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What blood pressure reduction should we expect from renal denervation?
Insights from ofﬁce versus ambulatory pressure reductions in uncontrolled and
blinded placebo-controlled drug trials of 4,121 patients
James P. Howard1, Darrel P. Francis1, Alexandra N. Nowbar1
1Imperial College London, London, United Kingdom
Background: Trials of renal denervation report drops ofw30mmHg in ofﬁce systolic
blood pressure, yet reductions in ambulatory pressures appear to bew3-fold smaller.
It has been claimed this disparity is seen in antihypertensive drug trials. We examine
this ofﬁce-ambulatory discrepancy though meta-analysis of drug trials reporting ofﬁce
and ambulatory pressures.
Methods:We tested the hypothesis that ofﬁce pressure drops overestimate ambulatory
drops by meta-analysis of both one-armed and double-blinded placebo-controlled drug
trials.
Results: DRUG TRIALS: 31 drug trials enrolling 4,121 patients met the criteria.
Ofﬁce blood pressure drop per unit ambulatory pressure drop was 1.46 (95% CI 1.23
to 1.68) in uncontrolled trials, but only 0.96 (95% CI 0.81 to 1.12) for blinded
placebo-controlled trials. DENERVATION: 23 trials enrolling 720 patients were
analysed. Ofﬁce pressure drops were 26.7 mmHg versus controls in open label trials.
Ambulatory pressure drops averaged 15.7 mmHg. No randomized blinded results are
available.P
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pressure drops to be larger than ambulatory drops. The ofﬁce-ambulatory pressure
drop discrepancy in renal denervation trials may therefore be absent from future
double-blinded trials. Persistence of the discrepancy would only be possible if renal
denervation managed to abolish the alerting response, or 'white coat effect', implying
that the alerting response is mediated by the renal sympathetic nerves.
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Background: Catheter-based renal denervation (RDN) had shown to be an effective
treatment to control blood pressure (BP) in patients with resistant hypertension. In the
Symplicity HTA-2 randomized controlled trial, RDN lowered systolic blood pressure
by 32  23 mmHg. In addition, radiofrequency (RF) ablation of renal arteries reducesJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrsympathetic activity reducing left ventricular mass and insulin resistance. However,
the efﬁcacy of this novel procedure in the real world clinical practice is still unknown.
Methods: Prospective, multicenter, observational registry of consecutive patients
submitted to RDN at 20 centers in Venezuela between February and December 2012.
We included patients with resistant hypertension deﬁned as systolic BP > 160 mmHg
despite taking three or more antihypertensive drugs with normal renal function
(estimated glomerular ﬁltration rate > 45 ml/min/1.73 mts2). The primary end-point
was reduction in systolic BP at 1 and 6 months follow-up, the secondary end-point
was any adverse event after the procedure.
Results: One hundred patients were included for this analysis; mean age was 54.9 
11, 46% were females, 49% caucasians and 33% diabetics. Pre-procedural ofﬁce BP
was 173/99 mmHg (SD 20/14), the mean number of anti-hypertertensive medica-
tions was 4.3 (85% diuretics with 23% aldosterone antagonist). Regarding proce-
dural characteristics 9.9  1.9 RF ablations were done per patient, with a mean
impedance reduction of -13.8%. At 30 days ofﬁce BP reduction was –33/17 mmHg
(SD 22/15 p¼0.002) and at 6 months (n¼75) –32/15 mmHg (p¼0.004). One
intraprocedural renal artery dissection occurred before radiofrequency energy
delivery that required no additional treatment and there were no adverse events
during follow-up.
Conclusions: Catheter-based RDN effectively reduces BP in the real world scenario
with this beneﬁts maintain at 6 months follow-up. In this preliminary experience, no
major complication was observed.
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ALSTER-BP Registry: Follow up data from 100 patients including ﬁrst re-do
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Background: Renal denervation has gathered great impact as additional therapy
option for patients suffering from resistant hypertension. Here we report results of the
ALSTER-BP registry including 6 month follow up data from 93 patients that were
treated with renal denervation in real world setting. Additionally 8 patients underwent
a second renal denervation procedure and were followed up again.
Methods: Patients matching the established inclusion criteria for renal denervation
were included in the ALSTER-BP registry (n¼93) and were then treated with the
Symplicity renal denervation system. The follow-up period was 6 months. 8 patients
who showed no or insufﬁcient blood pressure reduction underwent a second renal
denervation procedure (re-do) 9 months after the ﬁrst procedure and were followed up
for another 6 months.
Results: The initial patient cohort (n¼93) was divided into three groups. Early
responders showed a reduction of ofﬁce systolic blood pressure >10mmHg 3 months
after the procedure (n¼53, 57%), late responders 6 months after the procedure (n¼16,
17%) and non-responders showed no signiﬁcant reduction (n¼24, 26%). After six
months systolic blood pressure was lowered by 462.9 mmHg (meanSEM,
p<0.001), 313.4mmHg (p<0.001) and 7.13.3mmHg (p¼0.79, ns), respectively.
Ambulatory blood pressure monitoring also showed a signiﬁcant reduction in the early
responder group (205.7mmHg, p¼0.002). In 5 out of 8 patients (63%) who
underwent a re-do procedure ofﬁce systolic blood pressure was lowered >10mmHg 6
month after the second procedure. One patient (13%) showed a signiﬁcant renal artery
stenosis that was treated by stent implantation 5 months after the second procedure.
No other adverse side effects were observed in all other patients.
Conclusions: Renal denervation is a safe and effective therapy option even in clinical
all day setting. There might be different mechanisms underlying the observed blood
pressure reduction that ﬁnd their expression in different response rates. The success of
the re-do procedure in 63% of the patients argues in favour of current ablation
techniques to not sufﬁciently reduce sympathetic innervation of the kidney to affect
blood pressure regulation in some patients.
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Background: The effectiveness of radiofrequency (RF) ablation of renal autonomic
nerves has been proven. However, long-term safety of the renal artery (RA) is of
concern. The aim of our study was to determine if cooling during RF ablation
preserved the RA while allowing equivalent nerve damage.
Methods: A total of 10 swine with 20 RAs were enrolled, and relegated to the irri-
gated 50C (n¼6), non-irrigated 65C (n¼6), non-irrigated 90C (n¼6), and control
(n¼2) groups. Each RA was treated with RF ablation catheter (RenLane Renal
Denervation Catheter [Cordis, Inc. Fremont, CA, USA]) with different treatment
protocol as above. Animals were harvested at 10 days. RAs were serially sectioned,
and stained with H&E and Movat Pentachrome.acts/POSTER/Renal Denervation B149
